Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
WATERTOWN, Mass., March 10, 2016 -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 28th Annual Roth Conference on Tuesday, March 15, 2016 at 1:00 p.m. Pacific Time at The Ritz Carlton Hotel in Orange County, California.
A live audio webcast of the Roth presentation will be available on the company's website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening MDR bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase’s pipeline includes three antibiotic candidates: eravacycline, its late-stage clinical candidate, TP-271 and TP-6076. Please visit www.tphase.com for more company information.
Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 [email protected] Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 [email protected] Argot Partners Susan Kim 212-600-1902 [email protected]
